Baseline Demographic, Clinical, and Laboratory Variables
| Variable . | Autologous PBSC (n = 355) . | Allogeneic BM (n = 283) . | ||||
|---|---|---|---|---|---|---|
| Eval . | n (%) . | Median . | Eval . | n (%) . | Median . | |
| Demographics | ||||||
| Age (yr) | 355 | 47 | 275 | 38 | ||
| Sex | 355 | 275 | ||||
| Female | 233 (66) | 110 (40) | ||||
| Male | 122 (34) | 165 (60) | ||||
| Disease | 355 | 283 | ||||
| Breast cancer | 144 (41) | 1 (<1)-152 | ||||
| Chronic myeloid leukemia | 7 (2)-150 | 86 (30) | ||||
| Acute myeloid leukemia | 9 (3)-150 | 76 (27) | ||||
| Acute lymphoid leukemia | 2 (<1)-150 | 29 (10) | ||||
| Myelodysplastic syndrome | 34 (12) | |||||
| Aplastic anemia/congenital | 15 (5) | |||||
| Non-Hodgkin's lymphoma | 74 (21) | 17 (6)-151 | ||||
| Hodgkin's disease | 24 (7) | 3 (<1)-151 | ||||
| Multiple myeloma | 72 (20) | 15 (5) | ||||
| Other solid tumors | 21 (6) | 3 (<1)-152 | ||||
| Other leukemias | 2 (<1)-150 | 4 (1)-152 | ||||
| Therapy before preparative regimen | ||||||
| Chemotherapy | 355 | 350 (99) | 275 | 237 (86) | ||
| Alkylating agent | 355 | 295 (83) | 275 | 74 (27) | ||
| Radiation therapy | 352 | 96 (27) | 274 | 37 (14) | ||
| Pelvic radiation therapy | 345 | 7 (2) | 272 | 15 (6) | ||
| Interferon | 355 | 11 (3) | 275 | 47 (17) | ||
| Stem cell transplant | 355 | 18 (5) | 275 | 15 (6) | ||
| Time from diagnosis (mo) | 11.4 | 8.3 | ||||
| Baseline bone marrow histology | ||||||
| Malignant cells | 355 | 57 (16) | ||||
| Hypercellular (60% to 100% cellular) | 355 | 49 (14) | ||||
| Hypocellular (0% to 19% cellular) | 355 | 16 (5) | ||||
| PBSC mobilization | ||||||
| Growth factor | 344 | 328 (95) | ||||
| Chemotherapy | 344 | 128 (37) | ||||
| Growth factor and chemotherapy | 344 | 121 (35) | ||||
| Graft manipulation | ||||||
| Any | 355 | 27 (8) | 275 | 68 (25) | ||
| Purged | 355 | 13 (4) | ||||
| CD34 enriched | 355 | 23 (7) | 275 | 2 (<1) | ||
| T-cell depleted | 275 | 28 (10) | ||||
| Baseline blood counts | ||||||
| Platelets (×109/L) | 345 | 178 | 211 | 149 | ||
| Neutrophils (×109/L) | 331 | 3.9 | 205 | 3.1 | ||
| Baseline CMV seropositivity | 355 | 155 (44) | 275 | 169 (62) | ||
| Allogeneic donor source | 272 | |||||
| HLA-identical sibling | 145 (53) | |||||
| Alternative donors | 127 (47) | |||||
| Preparative regimen | ||||||
| Radiation containing | 355 | 67 (19) | 275 | 193 (70) | ||
| Busulfan containing | 355 | 48 (14) | 275 | 79 (29) | ||
| Stem cell numbers infused | ||||||
| CD34 (×106/kg) | 290 | 4.89 | 45 | 2.34 | ||
| Nucleated cells (×108/kg) | 221 | 7.52 | 264 | 2.35 | ||
| Mononuclear cells (×108/kg) | 219 | 7.43 | 46 | 0.49 | ||
| CFU-GM (×104/kg) | 126 | 15.45 | 48 | 13.48 | ||
| Variable . | Autologous PBSC (n = 355) . | Allogeneic BM (n = 283) . | ||||
|---|---|---|---|---|---|---|
| Eval . | n (%) . | Median . | Eval . | n (%) . | Median . | |
| Demographics | ||||||
| Age (yr) | 355 | 47 | 275 | 38 | ||
| Sex | 355 | 275 | ||||
| Female | 233 (66) | 110 (40) | ||||
| Male | 122 (34) | 165 (60) | ||||
| Disease | 355 | 283 | ||||
| Breast cancer | 144 (41) | 1 (<1)-152 | ||||
| Chronic myeloid leukemia | 7 (2)-150 | 86 (30) | ||||
| Acute myeloid leukemia | 9 (3)-150 | 76 (27) | ||||
| Acute lymphoid leukemia | 2 (<1)-150 | 29 (10) | ||||
| Myelodysplastic syndrome | 34 (12) | |||||
| Aplastic anemia/congenital | 15 (5) | |||||
| Non-Hodgkin's lymphoma | 74 (21) | 17 (6)-151 | ||||
| Hodgkin's disease | 24 (7) | 3 (<1)-151 | ||||
| Multiple myeloma | 72 (20) | 15 (5) | ||||
| Other solid tumors | 21 (6) | 3 (<1)-152 | ||||
| Other leukemias | 2 (<1)-150 | 4 (1)-152 | ||||
| Therapy before preparative regimen | ||||||
| Chemotherapy | 355 | 350 (99) | 275 | 237 (86) | ||
| Alkylating agent | 355 | 295 (83) | 275 | 74 (27) | ||
| Radiation therapy | 352 | 96 (27) | 274 | 37 (14) | ||
| Pelvic radiation therapy | 345 | 7 (2) | 272 | 15 (6) | ||
| Interferon | 355 | 11 (3) | 275 | 47 (17) | ||
| Stem cell transplant | 355 | 18 (5) | 275 | 15 (6) | ||
| Time from diagnosis (mo) | 11.4 | 8.3 | ||||
| Baseline bone marrow histology | ||||||
| Malignant cells | 355 | 57 (16) | ||||
| Hypercellular (60% to 100% cellular) | 355 | 49 (14) | ||||
| Hypocellular (0% to 19% cellular) | 355 | 16 (5) | ||||
| PBSC mobilization | ||||||
| Growth factor | 344 | 328 (95) | ||||
| Chemotherapy | 344 | 128 (37) | ||||
| Growth factor and chemotherapy | 344 | 121 (35) | ||||
| Graft manipulation | ||||||
| Any | 355 | 27 (8) | 275 | 68 (25) | ||
| Purged | 355 | 13 (4) | ||||
| CD34 enriched | 355 | 23 (7) | 275 | 2 (<1) | ||
| T-cell depleted | 275 | 28 (10) | ||||
| Baseline blood counts | ||||||
| Platelets (×109/L) | 345 | 178 | 211 | 149 | ||
| Neutrophils (×109/L) | 331 | 3.9 | 205 | 3.1 | ||
| Baseline CMV seropositivity | 355 | 155 (44) | 275 | 169 (62) | ||
| Allogeneic donor source | 272 | |||||
| HLA-identical sibling | 145 (53) | |||||
| Alternative donors | 127 (47) | |||||
| Preparative regimen | ||||||
| Radiation containing | 355 | 67 (19) | 275 | 193 (70) | ||
| Busulfan containing | 355 | 48 (14) | 275 | 79 (29) | ||
| Stem cell numbers infused | ||||||
| CD34 (×106/kg) | 290 | 4.89 | 45 | 2.34 | ||
| Nucleated cells (×108/kg) | 221 | 7.52 | 264 | 2.35 | ||
| Mononuclear cells (×108/kg) | 219 | 7.43 | 46 | 0.49 | ||
| CFU-GM (×104/kg) | 126 | 15.45 | 48 | 13.48 | ||
Abbreviations: Eval, number of patients for which data are available; n, number of patients for which that variable pertains.
Grouped together as “leukemia.”
Grouped together as “lymphoma” for univariate and multivariate analysis.
Not used in univariate and multivariate analysis because of small number of subjects.